Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Ms. Supraja R Prasad | Drug Discovery and Development | Best Researcher Award

Kuvempu University | India

Ms. Supraja R. Prasad is a passionate researcher and educator specializing in organic synthesis, computational chemistry, and the design of biologically active heterocycles. Her academic and professional journey reflects a deep dedication to the integration of sustainable chemical methodologies with modern computational tools to advance the field of drug discovery. She is particularly recognized for her innovative work on the green synthesis of heterocyclic compounds, utilizing eco-friendly multicomponent reactions and natural catalysts to create molecular frameworks with promising therapeutic potential.Her research portfolio spans multiple interrelated areas, including mechanochemical synthesis of heterocyclic derivatives, density functional theory (DFT) studies, and spectral characterization of synthesized compounds. She has also explored the anti-diabetic activity of synthesized derivatives, focusing on developing safer and more efficient alpha-glucosidase inhibitors for managing type 2 diabetes mellitus. By combining experimental synthesis with computational modeling and molecular docking analyses, Ms. Prasad bridges the gap between theoretical chemistry and practical pharmacological applications.Her recent publication in the Journal of the Indian Chemical Society highlights her contributions to the synthesis and evaluation of alpha-glucosidase inhibitors, further strengthening her position within the scientific community. Through her work, she demonstrates how green chemistry can drive meaningful advancements in pharmaceutical sciences while minimizing environmental impact.Ms. Prasad’s academic mission is rooted in the belief that collaborative, interdisciplinary research can accelerate innovation. She emphasizes teamwork, creativity, and knowledge sharing as the cornerstones of impactful scientific progress. Her approach integrates sustainability, molecular insight, and therapeutic relevance — a combination that continues to shape her vision for future research.Her ongoing studies and contributions to organic synthesis, bioactivity assessment, and computational modeling position her as an emerging leader in sustainable chemistry and computational drug discovery, striving to make scientific research both environmentally responsible and socially beneficial.

Profile: Orcid

Featured Publications

Clay catalyzed dihydropyrimidinone synthesis: α-glucosidase inhibition and chemoinformatics. Journal of the Indian Chemical Society.

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, Drug Discovery and Development ,Best Researcher Award

Assist Prof Dr. Lili Xu, at China Pharmaceutical University,China

Author Profile

🎓 Academic and Professional Background:

Lili Xu, Ph.D., earned her degree in Pharmaceutical Chemistry and Biology from China Pharmaceutical University in 2017. She conducted postdoctoral research at the same institution until July 2021 when she was promoted to Associate Researcher. She leads two projects funded by the National Natural Science Foundation of China and two by the Natural Science Foundation of Jiangsu Province. With over 40 SCI papers and six patents, she’s received awards like the Shimadzu Young Scholar, Gold Prize of the Macedonia Invention, and Silver Prize of the Geneva Invention Award.

🔬 Research and Innovations:

Completed/Ongoing Research Projects:

  • National Natural Science Foundation of China, General Program: Screening, design, and synthesis of novel inhibitors that interfere with the formation of NEK7-NLRP3 inflammasome complexes and their application in the treatment of acute and chronic inflammation-related diseases (82173675), 2022.01~2025.12, RMB 550,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, Youth Program: Discovery, design, synthesis, and exploration of NLRP3 inflammasome-targeted inhibitors for the treatment of non-controllable inflammatory disorders (81803354). 2019.01~2021.12, RMB 210,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, Youth Program: Design and synthesis of NLRP3-targeted inhibitors based on skeleton reconstruction strategy, and exploration of their therapeutic effects on non-controllable inflammatory disorders (BK20180564). 2018.07~2021.06, RMB 200,000, principal investigator, completed.

 

  • Natural Science Foundation of Jiangsu Province, General Program: Discovery, design, synthesis, and activity evaluation of novel inhibitors targeting TLR4-MD2 immune-inflammatory pathway for drug addiction treatment (BK20231480). 2023-07-01~2026-06-30, RMB 100,000, principal investigator, ongoing.
  • China Postdoctoral Science Foundation, General Program: Discovery, optimization, activity evaluation, and mechanistic studies of ULK1 inhibitors (2017M620232), 2018.01~2021.01, RMB 80,000, principal investigator, completed.

 

  • Fundamental Research Funds for the Central Universities, Key Program: Discovery and validation of novel oxadiazole-based anti-inflammatory target proteins using proteomics and molecular probe technology, 2021.01~2022.12, RMB 150,000, principal investigator, ongoing.

 

  • National Natural Science Foundation of China, General Program: Discovery of ubiquitin E3 ligase Cbl-b inhibitors based on substrate-binding crucial features and exploration of their application in tumor immunotherapy (82173680), 2022.01~2025.12, RMB 550,000, ongoing, participating.

 

  • National Natural Science Foundation of China, General Program: Discovery of targeted inducers of tau protein degradation conjugates based on ubiquitin E3 ligase Keap1 and exploration of their therapeutic application in Alzheimer’s disease (81773581), 2018.01~2021.12, RMB 620,000, completed, participating.

 

  • National Natural Science Foundation of China, Youth Program: Research on the application of GNN-based Raman hotspot regulation method in drug-target interaction (81803485), 2019.01~2021.12, RMB 210,000, completed, participating.

🏭 Consultancy/Industry Projects:

  • Institutional commissioned project: Detection of drugs in urban wastewater in Jiangyin City, commissioned by the Jiangyin Public Security Bureau, RMB 69,100, principal investigator, ongoing.
  • Industry commissioned project: Joint laboratory for drug detection between China Pharmaceutical University and Jiangsu Kangda Detection Technology Co., Ltd. (co-build laboratory), RMB 200,000, principal investigator, ongoing.

📚 Books Published (ISBN):

Currently, no books have been published.

💡 Patents Published/Under Process:

As the first inventor, Lili Xu has obtained 5 granted invention patents; as the fourth inventor, she has obtained 1 granted invention patent. Patent numbers: ZL201911146468.0, ZL202110442073.6, ZL202010483840.3, ZL201910366733.X, ZL202210071005.8, ZL202210146811.7.

.

🎓Publication Top Noted:

Paper Title : Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl
    • Authors:Jun Huang, Xing-Xing Fan, Jiaxi He, Hui Pan, Run-Ze Li, Liyan Huang, Zebo Jiang, Xiao-Jun Yao, Liang Liu, Elaine Lai-Han Leung, Jian-Xing Hee
    • Journal: Oncotarget
    • Year:2016
    • Citations : 86

     

Paper Title :The NLRP3 inflammasome: a vital player in inflammation and mediating the anti-inflammatory effect of CBD
  • Authors: Chu, F.-X., Wang, X., Li, B., Xu, L.-L., Di, B.
  • Journal: Inflammation Research
  • Volume: In Press
  • Issue: In Press
  • Year: 2024
Paper Title : Protein-protein interactions and related inhibitors involved in the NLRP3 inflammasome pathway
  • Authors: Ma, Z.-Y., Jiang, C., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 14–28
  • Year: 2023
Paper Title :Mechanisms of NLRP3 inflammasome activation and the development of peptide inhibitors
  • Authors: Ye, T., Tao, W.-Y., Chen, X.-Y., Di, B., Xu, L.-L.
  • Journal: Cytokine and Growth Factor Reviews
  • Volume: 74
  • Pages: 1–13
  • Year: 2023
Paper Title : A light-up fluorescence probe for wash-free analysis of Mu-opioid receptor and ligand-binding events
  • Authors: Jia, Y., Xu, L., Wang, L., Yan, F., Hu, C.
  • Journal: Analytica Chimica Acta
  • Volume: 1261
  • Pages: 341220
  • Year: 2023